Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + vandetanib
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Temozolomide + vandetanib is an investigational combination therapy for glioblastoma and other malignant gliomas. Temozolomide is an oral alkylating agent that penetrates the blood-brain barrier and induces cytotoxicity by DNA alkylation. Vandetanib (also known as ZD6474) is a small molecule inhibitor targeting both vascular endothelial growth factor receptor 2 (VEGFR2) and epidermal growth factor receptor (EGFR), providing anti-angiogenic and anti-proliferative effects. The combination aims to enhance tumor control by simultaneously inducing DNA damage in tumor cells (temozolomide) and inhibiting angiogenesis as well as EGFR-mediated signaling pathways that contribute to tumor growth and resistance (vandetanib). Preclinical studies have shown significant reduction in glioblastoma tumor volume with this combination compared to monotherapy[1][6][8]. Clinical trials have evaluated its safety profile when combined with radiotherapy in newly diagnosed glioblastoma patients[2][3][4].
- Brand names
- Zactima
- Other names
- temozolomide + ZD6474TMZ + vandetanib
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on temozolomide + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + vandetanib.